Form 8-K - Current report:
SEC Accession No. 0000950170-23-030725
Filing Date
2023-06-29
Accepted
2023-06-29 16:02:28
Documents
13
Period of Report
2023-06-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20230628.htm   iXBRL 8-K 103973
2 EX-3.1 trvi-ex3_1.htm EX-3.1 13389
  Complete submission text file 0000950170-23-030725.txt   247443

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trvi-20230628_pre.xml EX-101.PRE 11896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trvi-20230628_lab.xml EX-101.LAB 14809
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trvi-20230628.xsd EX-101.SCH 2497
7 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20230628_htm.xml XML 5069
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 231057336
SIC: 2834 Pharmaceutical Preparations